EP0473651A4 - Monoclonal antibodies which recognise malignant cells from bladder carcinomas - Google Patents

Monoclonal antibodies which recognise malignant cells from bladder carcinomas

Info

Publication number
EP0473651A4
EP0473651A4 EP19900908164 EP90908164A EP0473651A4 EP 0473651 A4 EP0473651 A4 EP 0473651A4 EP 19900908164 EP19900908164 EP 19900908164 EP 90908164 A EP90908164 A EP 90908164A EP 0473651 A4 EP0473651 A4 EP 0473651A4
Authority
EP
European Patent Office
Prior art keywords
recognise
monoclonal antibodies
malignant cells
bladder carcinomas
carcinomas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900908164
Other versions
EP0473651A1 (en
Inventor
Karen Zell Walker
Pamela Joan Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central Sydney Area Health Service
University of Sydney
Original Assignee
Central Sydney Area Health Service
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Sydney Area Health Service, University of Sydney filed Critical Central Sydney Area Health Service
Publication of EP0473651A1 publication Critical patent/EP0473651A1/en
Publication of EP0473651A4 publication Critical patent/EP0473651A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP19900908164 1989-05-24 1990-05-24 Monoclonal antibodies which recognise malignant cells from bladder carcinomas Withdrawn EP0473651A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU4351/89 1989-05-24
AUPJ435189 1989-05-24
AU57306/90A AU642419B2 (en) 1989-05-24 1990-05-24 Monoclonal antibodies which recognise malignant cells from bladder carcinomas

Publications (2)

Publication Number Publication Date
EP0473651A1 EP0473651A1 (en) 1992-03-11
EP0473651A4 true EP0473651A4 (en) 1992-10-14

Family

ID=25631590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900908164 Withdrawn EP0473651A4 (en) 1989-05-24 1990-05-24 Monoclonal antibodies which recognise malignant cells from bladder carcinomas

Country Status (3)

Country Link
EP (1) EP0473651A4 (en)
AU (1) AU642419B2 (en)
WO (1) WO1990014433A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018562A1 (en) * 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
EP0710362B1 (en) * 1993-07-23 1998-11-04 Bard Diagnostic Sciences, Inc. Methods for determining the invasiveness of a bladder tumor
KR102249981B1 (en) 2014-10-23 2021-05-11 미노믹 인터내셔널 리미티드 Monoclonal anti-gpc-1 antibodies and uses thereof
CN107847593B (en) 2015-04-20 2021-12-14 美侬米克国际有限公司 Therapeutic antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118891A2 (en) * 1983-03-11 1984-09-19 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human bladder and ureter cancers and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118891A2 (en) * 1983-03-11 1984-09-19 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human bladder and ureter cancers and method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 0, no. 12, part E, 1988, page 147, abstract no. T314, New York, US; P.J. RUSSELL et al.: "Development and characterization of monoclonal antibodies to human bladder cancer" *
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, ANNUAL MEETING, San Francisco, California, 24th - 27th March 1989, vol. 30, page 285, abstract no. 1136; K.Z. WALKER et al.: "A new murine monoclonal antibody (BLCA-8) with potential for clinical application in the management of bladder cancer" *
See also references of WO9014433A1 *

Also Published As

Publication number Publication date
EP0473651A1 (en) 1992-03-11
AU5730690A (en) 1990-12-18
WO1990014433A1 (en) 1990-11-29
AU642419B2 (en) 1993-10-21

Similar Documents

Publication Publication Date Title
DE3571833D1 (en) Immunoassay for breast cancer employing monoclonal antibodies
GB8608068D0 (en) Monoclonal antibodies
EP0160446A3 (en) Breast tumor-associated antigen and monoclonal antibodies specific thereto
IL90017A0 (en) Monoclonal antibodies
GB8624899D0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
IL83291A0 (en) Monoclonal antibody against ovarian cancer cells(ovb-3)
GB8621910D0 (en) Monoclonal antibodies
GB8715347D0 (en) Monoclonal antibodies
EP0473651A4 (en) Monoclonal antibodies which recognise malignant cells from bladder carcinomas
EP0253646A3 (en) Anti-human gastric cancer monoclonal antibody
GB8616174D0 (en) Monoclonal antibodies
ZA89258B (en) Monoclonal antibodies
GB8927389D0 (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
ZA856374B (en) Immunoassay for breast cancer employing monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
GB8610203D0 (en) Monoclonal antibodies
AU4668889A (en) Monoclonal antibodies specific for tumor antigens
GB8419456D0 (en) Monoclonal antibodies
GB8416845D0 (en) Monoclonal antibodies
ZA85980B (en) Monoclonal anti-human breast cancer antibodies
GB8416841D0 (en) Monoclonal antibodies
IE892311L (en) Improved monoclonal antibodies
GB2215725B (en) Monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920827

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 19940712

18W Application withdrawn

Withdrawal date: 19940719

R18W Application withdrawn (corrected)

Effective date: 19940719